Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE
Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
A PHASE3 clinical study on HIV-Associated Lipodystrophy Syndrome, this trial is completed. The trial is conducted by French National Agency for Research on AIDS and Viral Hepatitis and has accumulated 6 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- French National Agency for Research on AIDS and Viral Hepatitis
- Procitech
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .